1. Home
  2. RGLS vs FRAF Comparison

RGLS vs FRAF Comparison

Compare RGLS & FRAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RGLS
  • FRAF
  • Stock Information
  • Founded
  • RGLS 2007
  • FRAF 1906
  • Country
  • RGLS United States
  • FRAF United States
  • Employees
  • RGLS N/A
  • FRAF N/A
  • Industry
  • RGLS Biotechnology: Pharmaceutical Preparations
  • FRAF Major Banks
  • Sector
  • RGLS Health Care
  • FRAF Finance
  • Exchange
  • RGLS Nasdaq
  • FRAF Nasdaq
  • Market Cap
  • RGLS 106.7M
  • FRAF 127.4M
  • IPO Year
  • RGLS 2012
  • FRAF N/A
  • Fundamental
  • Price
  • RGLS $1.59
  • FRAF $32.77
  • Analyst Decision
  • RGLS Strong Buy
  • FRAF
  • Analyst Count
  • RGLS 6
  • FRAF 0
  • Target Price
  • RGLS $10.33
  • FRAF N/A
  • AVG Volume (30 Days)
  • RGLS 391.3K
  • FRAF 4.6K
  • Earning Date
  • RGLS 11-11-2024
  • FRAF 10-22-2024
  • Dividend Yield
  • RGLS N/A
  • FRAF 4.01%
  • EPS Growth
  • RGLS N/A
  • FRAF 1.70
  • EPS
  • RGLS N/A
  • FRAF 3.20
  • Revenue
  • RGLS N/A
  • FRAF $71,523,000.00
  • Revenue This Year
  • RGLS N/A
  • FRAF N/A
  • Revenue Next Year
  • RGLS N/A
  • FRAF N/A
  • P/E Ratio
  • RGLS N/A
  • FRAF $9.48
  • Revenue Growth
  • RGLS N/A
  • FRAF 8.15
  • 52 Week Low
  • RGLS $1.08
  • FRAF $25.11
  • 52 Week High
  • RGLS $3.79
  • FRAF $35.00
  • Technical
  • Relative Strength Index (RSI)
  • RGLS 53.16
  • FRAF 73.09
  • Support Level
  • RGLS $1.39
  • FRAF $29.85
  • Resistance Level
  • RGLS $1.68
  • FRAF $31.29
  • Average True Range (ATR)
  • RGLS 0.12
  • FRAF 0.40
  • MACD
  • RGLS 0.01
  • FRAF 0.20
  • Stochastic Oscillator
  • RGLS 68.97
  • FRAF 100.00

About RGLS Regulus Therapeutics Inc.

Regulus Therapeutics Inc is a biotechnology company focused on the development of microRNA therapies. MicroRNA therapies target diseases such as cancer, metabolic diseases, fibrosis, and inflammatory diseases. The product candidate of the company is RGLS8429, an anti-miR next-generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), and is in Phase 1b clinical development.

About FRAF Franklin Financial Services Corporation

Franklin Financial Services Corp is a bank holding company based in the United States. It is engaged in general commercial, retail banking and trust services normally associated with community banks. It offers a broad range of banking services to businesses, individuals, and governmental entities which includes accepting and maintaining cheques, savings, and time deposit accounts, providing investment and trust services, making loans and providing safe deposit facilities. The bank also performs personal, corporate, pension and fiduciary services through its Investment and Trust Services Department.

Share on Social Networks: